Related Experiment Video
Updated: Sep 10, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Chiari I Malformation and Idiopathic Growth Hormone Deficiency Case Series
Nikolitsa Techlemetzi1, Sokratis Katsoudas1,2, Evangelia Tsitsekli2
1Pediatrics, General Hospital of Nikaia Peiraia Agios Panteleimon, Nikaia, GRC.
Insights
Pediatric patients with Chiari I malformation (CIM) and growth hormone deficiency (GHD) can safely receive recombinant human growth hormone (rhGH) therapy. This treatment effectively promotes growth without worsening CIM symptoms under multidisciplinary supervision.
Area of Science:
- Pediatric Endocrinology
- Neurology
- Genetics
Background:
- Chiari I malformation (CIM) and idiopathic growth hormone deficiency (GHD) are distinct pediatric conditions that can coexist.
- The pathophysiological link between CIM and GHD is not fully understood and remains controversial.
- This study investigates the clinical presentation, diagnosis, and treatment response in pediatric patients with concurrent CIM and GHD.
Observation:
- Five pediatric patients with concurrent CIM and idiopathic GHD were analyzed.
- Three patients were asymptomatic for CIM, with the malformation incidentally found during short stature evaluations.
- All patients received recombinant human growth hormone (rhGH) therapy.
Findings:
- All patients showed a positive growth response to rhGH treatment.
- No evidence of CIM progression was observed during the monitoring period.
- rhGH therapy did not exacerbate CIM symptoms in these patients.
Implications:
- rhGH therapy is a safe and effective treatment for promoting growth in pediatric patients with coexisting CIM and GHD.
- Multidisciplinary supervision involving endocrinologists and neurologists is crucial for managing these patients.
- Further research into the underlying mechanisms linking CIM and GHD is warranted.
Abstract:
Chiari I malformation (CIM) and idiopathic growth hormone deficiency (GHD) are distinct, yet occasionally coexisting conditions in pediatric patients. The underlying pathophysiological link between the two entities remains controversial. In this case series, we present five pediatric patients with concurrent CIM and idiopathic GHD, detailing their clinical presentations, diagnostic workups, and responses to recombinant human growth hormone (rhGH) therapy. Notably, three of the cases were asymptomatic for CIM, with the malformation incidentally detected during evaluations for short stature. All patients demonstrated a positive growth response to rhGH treatment, with no evidence of CIM progression over the monitoring period. Our literature review highlights several proposed mechanisms linking CIM and GHD, including the potential effects of breech delivery, congenital midline developmental anomalies, and an underdeveloped posterior cranial fossa. Despite concerns in some reports about the possible exacerbation of CIM symptoms with rhGH therapy, such as persistent headaches, cerebellar ataxia, or spinal cord-related symptoms, our findings suggest that, when administered under careful multidisciplinary supervision, rhGH can effectively promote growth without adversely affecting CIM. To conclude, we highlight the importance of close collaboration between endocrinologists and neurologists in managing patients with these coexisting conditions.
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Nature and Nurture
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy

